755 related articles for article (PubMed ID: 29021380)
1. Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma.
Zargar M; McFarlane T; Chan KKW; Wong WWL
Oncologist; 2018 Feb; 23(2):225-233. PubMed ID: 29021380
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Network Meta-analysis and Cost-effectiveness Analysis.
Pei R; Shi Y; Lv S; Dai T; Zhang F; Liu S; Wu B
JAMA Netw Open; 2021 May; 4(5):e218065. PubMed ID: 33956130
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of nivolumab in the treatment of head and neck cancer.
Hirschmann A; Lupatsch JE; Schwenkglenks M; Panje CM; Matter-Walstra K; Espeli V; Dedes KJ; Siano M;
Oral Oncol; 2018 Dec; 87():104-110. PubMed ID: 30527224
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck.
Tringale KR; Carroll KT; Zakeri K; Sacco AG; Barnachea L; Murphy JD
J Natl Cancer Inst; 2018 May; 110(5):479-485. PubMed ID: 29126314
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States.
Haddad R; Cohen EEW; Venkatachalam M; Young K; Singh P; Shaw JW; Korytowsky B; Abraham P; Harrington KJ
J Med Econ; 2020 May; 23(5):442-447. PubMed ID: 31928375
[No Abstract] [Full Text] [Related]
6. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
7. Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.
Wakasaki T; Yasumatsu R; Uchi R; Taura M; Matsuo M; Komune N; Nakagawa T
Auris Nasus Larynx; 2020 Feb; 47(1):116-122. PubMed ID: 31128940
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of nivolumab for recurrent or metastatic head and neck cancer☆.
Ward MC; Shah C; Adelstein DJ; Geiger JL; Miller JA; Koyfman SA; Singer ME
Oral Oncol; 2017 Nov; 74():49-55. PubMed ID: 29103751
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in the United States.
Borse RH; Ramakrishnan K; Gandhi J; Dhankhar P; Chirovsky D
J Med Econ; 2022; 25(1):954-965. PubMed ID: 35765888
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab plus ipilimumab versus the EXTREME regimen in recurrent/metastatic squamous cell carcinoma of the head and neck: a cost-effectiveness analysis.
Ye D; Liang X; Chen X; Li Y
Sci Rep; 2024 Mar; 14(1):6807. PubMed ID: 38514766
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.
Ferris RL; Licitra L; Fayette J; Even C; Blumenschein G; Harrington KJ; Guigay J; Vokes EE; Saba NF; Haddad R; Ramkumar S; Russell J; Brossart P; Tahara M; Colevas AD; Concha-Benavente F; Lynch M; Li L; Gillison ML
Clin Cancer Res; 2019 Sep; 25(17):5221-5230. PubMed ID: 31239321
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab in squamous cell carcinoma of the head and neck.
Specenier P
Expert Rev Anticancer Ther; 2018 May; 18(5):409-420. PubMed ID: 29560755
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
Ferris RL; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington K; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Iglesias Docampo LC; Haddad R; Rordorf T; Kiyota N; Tahara M; Monga M; Lynch M; Geese WJ; Kopit J; Shaw JW; Gillison ML
N Engl J Med; 2016 Nov; 375(19):1856-1867. PubMed ID: 27718784
[TBL] [Abstract][Full Text] [Related]
14. A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator's Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck.
Cocks K; Contente M; Simpson S; DeRosa M; Taylor FC; Shaw JW
Pharmacoeconomics; 2019 Aug; 37(8):1041-1047. PubMed ID: 30972702
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.
Haddad R; Concha-Benavente F; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Kasper S; Vokes EE; Worden F; Saba NF; Tahara M; Jayaprakash V; Lynch M; Li L; Gillison ML; Harrington KJ; Ferris RL
Cancer; 2019 Sep; 125(18):3208-3218. PubMed ID: 31246283
[TBL] [Abstract][Full Text] [Related]
16. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
Ferris RL; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington KJ; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Docampo LCI; Haddad R; Rordorf T; Kiyota N; Tahara M; Lynch M; Jayaprakash V; Li L; Gillison ML
Oral Oncol; 2018 Jun; 81():45-51. PubMed ID: 29884413
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Greenhalgh J; Bagust A; Boland A; Fleeman N; McLeod C; Dundar Y; Proudlove C; Shaw R
Health Technol Assess; 2009 Oct; 13 Suppl 3():49-54. PubMed ID: 19846029
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness of Pembrolizumab Regimens for the First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in Argentina.
Wurcel V; Chirovsky D; Borse R; Altuna JI; Carabajal F; Gandhi J
Adv Ther; 2021 May; 38(5):2613-2630. PubMed ID: 33855690
[TBL] [Abstract][Full Text] [Related]
20. Single-center prospective study on the efficacy of nivolumab against platinum-sensitive recurrent or metastatic head and neck squamous cell carcinoma.
Okamoto I; Tsukahara K; Sato H
Sci Rep; 2022 Feb; 12(1):2025. PubMed ID: 35132165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
